Bosutinib Forms and Preparation Methods Thereof
    2.
    发明申请
    Bosutinib Forms and Preparation Methods Thereof 有权
    Bosutinib形式及其制备方法

    公开(公告)号:US20170057923A1

    公开(公告)日:2017-03-02

    申请号:US15120226

    申请日:2015-02-20

    申请人: Apotex Inc.

    IPC分类号: C07D215/54

    摘要: The present subject matter relates to solvates and the amorphous form of bosutinib; the solvates namely being a propylene glycol solvate and an acetonitrile solvate. Also provided are processes for preparing the propylene glycol solvate, the amorphous form and the crystalline acetonitrile solvate of bosutinib; as well as compositions comprising said forms. Bosutinib is a 3-quinolinecarbonitrile kinase inhibitor and is indicated for the treatment of adult patients with chronic, accelerated, or blast phase Ph+ chronic myelogenous leukemia (CMS) with resistance or intolerance to prior therapy.

    摘要翻译: 本主题涉及溶剂化物和博丝替尼的无定形形式; 溶剂化物即丙二醇溶剂合物和乙腈溶剂合物。 还提供了制备波生菌素的丙二醇溶剂化物,无定形形式和结晶乙腈溶剂合物的方法; 以及包含所述形式的组合物。 Bosutinib是一种3-喹啉腈激酶抑制剂,用于治疗慢性,加速或爆发期Ph +慢性粒细胞白血病(CMS)的成年患者,其具有耐药性或不耐受以前的治疗。